Navigation Links
Amylin Pharmaceuticals Reports Third Quarter Financial Results
Date:10/21/2008

Product sales increased 14% over third quarter 2007 to $201 million

SAN DIEGO, Oct. 21 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today reported financial results for the quarter ended September 30, 2008. The Company reported total revenue of $218.4 million for the third quarter, including net product sales of $201.4 million, a 14% increase over the same period in 2007. Net loss for the quarter ended September 30, 2008 was $77.7 million, or $0.57 per share. Net loss per share, excluding an impairment loss on investments of $14.9 million, or $0.11 per share, was $0.46 per share.

"This quarter we reported strong product sales in the face of an increasingly challenging environment. Additionally we completed an exenatide once weekly product supply agreement with Lilly that strengthens our balance sheet and provides financial flexibility for the future," said Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals. "We continue to manage the company towards sustainable, profitable growth by driving BYETTA and SYMLIN revenue, managing our expenses, and bringing exenatide once weekly to market."

Quarter ended September 30, 2008

Net product sales of $201.4 million for the third quarter include $179.9 million for BYETTA(R) (exenatide) injection and $21.5 million for SYMLIN(R) (pramlintide acetate) injection. This represents a 14% increase over net product sales of $177.4 million for the same period in 2007.

Revenues under collaborative agreements were $17.0 million for the quarter ended September 30, 2008, compared to $12.6 million for the same period in 2007. The increase reflects higher cost-sharing payments from Lilly for development expenses for BYETTA an
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Amylin Pharmaceuticals to Webcast Third Quarter Results
2. Amylin Pharmaceuticals to Present at Thomas Weisel Healthcare, BioCentury NewsMakers, and Morgan Stanley Global Healthcare Conferences
3. Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA
4. Amylin and Lilly Set Date and Time for Conference Call
5. Amylin Pharmaceuticals to Webcast Second Quarter Results
6. Amylin Pharmaceuticals to Present at Goldman Sachs Global Healthcare Conference
7. Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008
8. Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders
9. Amylin Pharmaceuticals to Present at FBR Capital Markets Investor Conference
10. Amylin Pharmaceuticals to Present at Baird Growth Stock Conference
11. Amylin Pharmaceuticals to Present at Bank of America Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)...  BioSpecifics Technologies Corp. (NASDAQ: BSTC ... collagenase-based products marketed as XIAFLEX ® (collagenase ... XIAPEX ® in the EU, today announced ... Phase 2a study of CCH for the potential ... results showed that all three doses of CCH ...
(Date:8/21/2014)... DUBLIN, Ireland , August 21, 2014 ... and Markets ( http://www.researchandmarkets.com/research/3zh3q8/global_hormone ) has announced the ... Market 2014-2018"  report to their offering.  ... also known as hormone therapy, is a ... longer being produced by the body. This ...
(Date:8/21/2014)... NEW YORK , Aug. 21, 2014 Mathematic ... at Harvard University , and funded by the ... aggressive cells within tumors can be visually identified for elimination. ... tumor,s growth. The study, which shows a topological map of ... needed time in cancer research, for while tumor cells can ...
(Date:8/21/2014)... Ontotext S4 , The Self ... . Now the same enterprise hardened text mining, ... unstructured data is available to start-ups and mid-size businesses ... Organizations that do not have resources to evaluate and ... S4 since there is no need for on premise ...
Breaking Biology Technology:BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2Science Power Jeffrey Epstein and Harvard University Fund Project to Visually Stop Tumor Growth 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4
... Inc.,(Nasdaq: NGSX ), a biopharmaceutical company focused ... today that,Anthony DiTonno, President and Chief Executive Officer, ... Healthcare Unplugged Conference in New,York City on Tuesday, ... Financial Officer, will be available to respond to ...
... BETHESDA, Md., Sept. 2 Micromet, Inc.,(Nasdaq: ... company,developing novel, proprietary antibodies for the treatment of ... of,Barclay A. Phillips as Senior Vice President and ... member of the Company,s board of directors,since 2000, ...
... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) ... Administration (FDA) review, the Company is initiating ... administration of REOLYSIN(R) in,combination with paclitaxel and ... (NSCLC) with K-RAS or EGFR-activated tumours. The ...
Cached Biology Technology:NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference 2NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference 3Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer 2Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer 3Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer 4Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours 2Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours 3Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours 4
(Date:8/22/2014)... 2014 Research ... the addition of the  "Biometrics Market ... their offering.       (Logo: ... technology that helps in the identification ... or behavioral features. It involves verification ...
(Date:8/22/2014)... Thomson Reuters , a leading source of information ... the University of California, Riverside in its 2014 list ... our times." , To generate the list, the company ... researchers whose published work has had enormous impact. , ... 3,200 individuals who published the greatest number of highly ...
(Date:8/22/2014)... La Jolla, CA Research presented at the ... therapy being developed by Hera Therapeutics Inc. combats ... that cause 70 percent of all cervical cancer. ... models, HTI-1968 blocked the replication of HPV-16, HPV-18 ... Ph.D. and Thomas Broker, Ph.D., who presented the ...
Breaking Biology News(10 mins):Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 2Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 35 UC Riverside scientists among world's most influential scientific minds 2
... been identified in sediment-laden marine environments, conditions previously believed to ... that Middle Reef part of Australia,s iconic Great Barrier ... in areas with lower levels of sediment stress. Led ... team of scientists is published today (1 August 2012) in ...
... from the Wildlife Conservation Society (WCS) and the National Research ... called an imperial cormorant with a small camera, then watched ... in 40 seconds, feeding on the ocean floor for 80 ... to the surface 40 seconds later. This is the ...
... appendages that plague many people in the winter and an ... for singles and couples alike. In a new study, scientists ... Nationwide Children,s Hospital have identified a biological mechanism that may ... of molecules and receptors on smooth muscle cells that line ...
Cached Biology News:Coral reef thriving in sediment-laden waters 2Are cold feet plaguing your relationship? 2Are cold feet plaguing your relationship? 3
... imaging system from Molecular Devices is ... for automated acquisition and analysis of ... ImageXpressULTRA is powered by MetaXpress, ... acquisition, image storage and analysis. MetaXpress ...
... Bioimager is an automated, confocal, real-time, single ... has been integrated into a single, compact ... to provide high-resolution, automated confocal imaging with ... better cell-based assays. The system allows the ...
... uses a simplified procedure and streamlines the ... kit is based on the three step ... sodium bisulfite where cytosine is converted into ... in-column desulphonation reaction eliminates several precipitation steps ...
... The DIGIVIEW line of digital x-ray detectors ... imaging device complete with 12 to 16 ... consists of a photodiode array sensor with ... models are available in low x-ray energies ...
Biology Products: